Therapeutic nanoconjugates and uses thereof
AssigneesUniversitat Autonoma De Barcelona (Uab), Fundació Institut De Recerca De L'hospital De La Santa Creu I Sant Pau, Consorcio Centro de Investigación Biomédica en Red, M.P.
InventorsAntonio Pedro Villaverde Corrales, Esther Vázquez Gómez, Ugutz Unzueta Elorza, Ramón Mangues Bafalluy, María Virtudes Céspedes Navarro, Isolda Casanova Rigat
Life of this patent
Estimating the term…
Abstract
The present invention relates to nanostructured conjugates, more specifically to nanostructured fusion proteins suitable for the selective delivery of their conjugated therapeutic agents to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins and the therapeutic uses thereof.
Claims8
A fusion protein comprising:
- (i) a polycationic peptide, wherein the polycationic peptide comprises a sequence selected from the group consisting of SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, and SEQ ID NO:
- 8;
- (ii) an intervening polypeptide region conjugated to at least three chemotherapy agents, wherein the intervening polypeptide is selected from the group consisting of SEQ ID NO:
- 36, SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39, SEQ ID NO:40, cystatin B, cystatin C, cystatin D, cystatin M, and a variant having one or more mutations selected from the group consisting of a G4W, a G4R, a V48D, a V48L, a G50S, a K71N, a S72G, a L73P, a L82R and a T83S mutation with respect to the numbering in SEQ ID NO:
- 40;
- and
- (iii) a polyhistidine region.
Dependencies are inferred from the claim text.